Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.


BACKGROUND Patients with psoriasis have lesional symptoms, including itch, which can reduce quality of life. The efficacy and safety of brodalumab, an interleukin-17 receptor A antagonist, in treating moderate-to-severe psoriasis have been reported in three randomized, controlled, phase 3 trials (AMAGINE-1/-2/-3). OBJECTIVE The effect of brodalumab on… (More)
DOI: 10.1111/jdv.14913


  • Presentations referencing similar topics